Palvella Therapeutics (PVLA) Cash from Operations (2013 - 2026)

Palvella Therapeutics (PVLA) has 14 years of Cash from Operations data on file, last reported at 10900000.0 in Q1 2026.

• On a quarterly basis, Cash from Operations fell 61.05% year-over-year to 10900000.0 in Q1 2026; TTM through Mar 2026 was 29138000.0, a 76.53% decrease from a year earlier, with the FY2025 full-year figure at 25006000.0, down 130.68% from the prior year.
• Cash from Operations for Q1 2026 stood at 10900000.0, down from 4906000.0 in the prior quarter.
• Over the last five years, Cash from Operations for PVLA reached as high as 20447000.0 in Q4 2023 and fell as low as 22643000.0 in Q1 2022.
• Historically, Cash from Operations has averaged 7081235.29 across 5 years, with a median of 7900000.0 in 2025.
• Across the five-year window, Cash from Operations jumped 258.1% in 2023 and tumbled 514.16% in 2025, its largest moves.
• Year by year, Cash from Operations stood at 12933000.0 in 2022, then soared by 258.1% to 20447000.0 in 2023, then sank by 126.38% to 5393000.0 in 2024, then increased by 9.03% to 4906000.0 in 2025, then slumped by 122.18% to 10900000.0 in 2026.
• Per Business Quant data, the three most recent Cash from Operations figures were 10900000.0 in Q1 2026, 4906000.0 in Q4 2025, and 7900000.0 in Q3 2025.